Table 4. Comparation of baseline characteristics between Belatacept-treated and historical cohort of KTs with dialysis-dependent primary-non function (PNF).
| Belatacept-treated PNF (n = 5) | Historical cohort PNF (n = 8) | |
|---|---|---|
| Age, years (IQR) | 45.3 (34.1–66) | 61 (48–71.25) |
| Male gender male, n (%) | 2 (40) | 4 (50) |
| vPRA, % (IQR) | 0 (0–49.5) | 41 (0–88.75) |
| Donor age, years (IQR) | 52 (44–65) | 70.5 (62.25–74.25) |
| KDPI, % (IQR) | 80 (59.5–88) | 93% (78.25–96.5) |
| Previous KT, n (%) | 3 (60) | 3 (37.5) |
| Combined transplant (pancreas-kidney), n (%) | 1 (20) | 1(12.5) |
| DGF duration, days (IQR) | 48 (20–92.5) | 14 a (7.5–56) |
| HD dependent patients at 1-year post-KT, n (%) | 0 (0) | 7b (87.5) |
| mTORi therapy adoption, n (%) | 0 (0) | 2 (25) |
| Histology at the time of PNF | ||
| Acute tubular necrosis, n (%) | 5 (100) | 5 (62.5) |
| Acute rejection, n (%) | 1 (20) | 2 (25) |
| CNI toxicity, n (%) | 3 (60) | 2 (25) |
| Adverse events at 1- year post-KT, patients n (%) | 2 (40) | 4 (50) |
| Pyelonephritis, patients n (%) | 1(20) | 4 (50) |
| CMV replication, patients n (%) | 0 (0) | 3 (37.5) |
| Herpes Zoster disease, patients n (%) | 0 (0) | 1 (12.5) |
| Herpes Simplex virus esophagitis, patients n (%) | 0 (0) | 1 (12.5) |
| Acute cholecystitis, patients n (%) | 0 (0) | 1 (12.5) |
| EBV replication, patients n (%) | 0 (0) | 1 (12.5) |
| Acute bacterial pneumonia, patients n (%) | 0 (0) | 1 (12.5) |
| Acute interstitial pneumonia, patients n (%) | 0 (0) | 1 (12.5) |
| Sepsis of digestive tract origin, patients n (%) | 1 (20) | 0(0) |
a4/7 remain dialysis-dependent; 3/7 partially recovery at a mean time after KT of 5.3 months but definitively restart renal-replacement therapy in <1 year.
b1/8 restart dialysis 3 years after KT.
KDPI: kidney donor profile index; HD: hemodialysis; mTORi: mTOR inhibitors; ATN: acute tubular necrosis.